CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to uncover the molecular mechanisms behind drug resistance in ovarian cancer, specifically focusing on the relationship between the chemotherapeutic agents cisplatin and paclitaxel. By identifying key genes and proteins involved in resistance, it seeks to improve treatment strategies for patients.
The chemotherapeutic drugs cisplatin and paclitaxel are used in the treatment of ovarian cancer.
However, the rate of relapse after therapy is high and is often due to the development of drug resistance.
Drug-resistant cancer cell lines in the laboratory frequently have an inverse resistance relationship between cisplatin and paclitaxel.
When cisplatin resistance occurs, cells are likely to have no change in resistance to paclitaxel and some cells even become more sensitive to paclitaxel.
There…
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
